Latest Distributions News

Starpharma reports a $1.37 million profit for H1 FY26, driven by a major upfront payment from Genentech and progress in its radiopharmaceutical pipeline. The biotech also expands its consumer health footprint amid growing partnerships.

Netwealth Group Limited has reported a robust first half of FY26, with record funds under administration and a significant increase in dividends, underpinned by strong inflows and strategic technology investments.

The Environmental Group Limited reported a robust first half of FY26 with revenue rising 8.6% to $58.9 million and underlying EBITDA jumping 25.9%, driven by strong performances in its Energy and Waste divisions alongside strategic operational upgrades.

Mirvac Group reported a robust half-year result with a 5% rise in operating profit and a significant boost in residential sales, underpinned by a $1 billion joint venture with Mitsubishi Estate. The company’s strategic pipeline restocking and strong leasing performance signal promising growth ahead.

Fletcher Building reports a stable half-year performance despite subdued markets, advancing its strategic pivot with the announced sale of its Construction division.

Morphic Ethical Equities Fund Limited reported a half-year profit after tax of $1.26 million for December 2025, declaring a fully franked 1 cent dividend and continuing its share buy-back program.

EZZ Life Science Holdings has secured a four-year exclusive global distribution agreement with Aumake Limited, committing to at least A$10 million in purchases. This partnership aims to accelerate EZZ’s international reach while preserving brand control.

Aumake Limited has secured a four-year exclusive global distribution agreement with EZZ Life Sciences, targeting $10 million in sales and expanding its footprint in high-margin nutraceuticals.

Mont Royal Resources has identified significant growth opportunities within the BD-Zone of its Ashram Rare Earth Element deposit, highlighting promising mineralogy and high-value rare earth element concentrations that could enhance project economics.

Asset Vision has reported a robust 38% increase in annual recurring revenue to $5.2 million in the first half of FY26, underpinned by new council contracts and AI-driven platform upgrades. The company’s positive cash EBITDA and strategic focus on scalable growth signal strong momentum in the critical infrastructure SaaS market.

Rhythm Biosciences has inked a non-exclusive distribution agreement with 4Cyte Pathology to integrate its ColoSTAT® colorectal cancer blood test into a vast pathology network across eastern Australia, aiming to boost adoption and accessibility.

Iceni Gold has reported anomalous copper, zinc, and lead in its deepest drill hole at the Welcome Creek Project, signalling promising mineralisation in the Officer Basin. While the main geophysical target remains untested due to drill deviation, the findings open new avenues for exploration.